Abstract:Abstract BACKGROUND AND AIMS The Framingham risk score (FRS) was developed to estimate an individual`s risk of coronary heart disease over the next 10 years in the general population by using traditional cardiovascular disease (CVD) risk factors age, sex, systolic blood pressure, treatment of hypertension, total cholesterol, high-density lipoprotein cholesterol and smoking status. However, the utility of FRS in predicting CVD mortality in kidney failure patients is not clear. We examined the association between FRS and all-cause and CVD mortality in two cohorts of kidney failure patients from China and Sweden, respectively. METHOD In 1276 Chinese incident peritoneal dialysis [median age 50 years, 56% males, BMI 21 (19–23); incident peritoneal dialysis] and 559 Swedish incident or prevalent dialysis patients [median age 58 years, 62% males, BMI 24 (22–28)], FRS and baseline biochemical and metabolic biomarkers were analysed in relation to mortality during follow-up period of up to 5 years. All-cause and CVD mortality risk of were analysed with competing-risk regression models with transplantation as competing risk adjusting for BMI, serum albumin, hemoglobulin and calendar year. RESULTS Chinese patients were significantly younger (P < 0.01) and had lower BMI (P < 0.01) and FRS (P < 0.01) than Swedish patients but their sex distribution was similar. ‘In the Chinese patients,’ during median 3.6 years of follow-up, all-cause mortality rate was 16%, and 91 (46%) of the 199 deaths were caused by CVD. Both middle and high tertiles of FRS were associated with higher all-cause (Fig. 1A) and CVD mortality (Fig 1B) risk after adjusting for confounders. ‘In the Swedish patients,’ after median 2.1 years of follow-up, all-cause mortality rate was 36%, and 89 (44%) of the 204 deaths were caused by CVD. Both middle and high tertiles were associated with higher all-cause (Fig. 2A) and CVD mortality (Fig. 2B) risk after adjusting for confounders. CONCLUSION Higher FRS (both middle and high tertiles of FRS) was independently associated with significantly higher all-cause and CVD mortality risk in Chinese as well as in Swedish patients with kidney failure. These results underline the importance of traditional CVD risk factors in kidney failure patients and suggest that FRS may be a useful risk-assessment tool for predicting clinical outcomes in these patients.

Prognostic Value of FGF23 among Patients with End-Stage Renal Disease: a Systematic Review and Meta-Analysis

Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis

Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function

Fibroblast Growth Factor-23 As a Biomarker of Adverse Outcomes in Patients with Coronary Artery Disease: a Meta-Analysis

Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D.

Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study

Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure

Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography

Association of FGF23, Fetuin-A level and clinical outcome among STEMI patients

Circulating FGF‐23 Is Associated With Increased Risk of Osteoporosis and Fractures in Hemodialysis Patients: A Prospective Observational Study

Association of fibroblast growth factor 23 with coronary artery calcification in patients with moderate and advanced stage chronic kidney diseases

FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease

MO681: Association of Framingham Risk Score with Mortality in Kidney Failure Patients from China and Sweden

Association of Serum FGF23 with Abdominal Aortic Calcification and Outcomes in Maintenance Hemodialysis Patients

Fibroblast growth factor 23 in children with or without heart failure: a prospective study

Fibroblast Growth Factor 23 is Independently Associated with Renal Magnesium Handling in Patients with Chronic Kidney Disease.

Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis

FGF23 and coronary heart disease

Hemodialysis is Associated with Higher Serum FGF23 Level when Compared with Peritoneal Dialysis

FGF23 from bench to bedside